We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Diagnostic Tests Improve Care for Heart Failure Patients

By LabMedica International staff writers
Posted on 17 Jan 2017
Print article
For the first time, researchers have developed tests that could improve treatment for heart failure patients by diagnosing the condition with greater accuracy, as well as by detecting the onset of congestive heart failure earlier.

Heart failure is a leading cause of hospitalization for people older than age 65 in developed “Western” countries. At present, the main blood tests used to aid in the diagnosis of heart failure are those for B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP). However, natriuretic peptide tests have a high false positive rate and a limited ability to detect the early and asymptomatic stages of the disease.

With the goal of overcoming the drawbacks of current heart failure tests, a group of researchers developed a diagnostic panel that provides a more comprehensive representation of the heart’s functioning by measuring multiple biological molecules. Led by Hugo A. Katus, MD, PhD, of Heidelberg University Hospital, the researchers began by identifying 92 metabolites (metabolic byproducts) that changed significantly in heart failure patients compared with healthy individuals. They chose 3 of these metabolites, which belong to the lipid classes of sphingomyelins, triglycerides, and phosphatidylcholines, for their cardiac lipid panel (CLP).

The researchers then tested the ability of CLP combined with NT-proBNP measurements to diagnose heart failure in 649 individuals who either had the condition, were healthy, or had pulmonary diseases (which can often be misidentified as heart failure). CLP plus NT-proBNP diagnosed heart failure with much greater certainty than NT-proBNP alone, even in the early and asymptomatic stages, demonstrating a high specificity of 97.6% while NT-proBNP by itself has a specificity of only 88.1%.

“A low false-positive rate is particularly important in the outpatient setting and may prevent patients from unnecessary diagnostic workup and treatment, which in turn will save resources and avoid potential side-effects,” said Dr. Katus, “A more accurate diagnosis of patients […] may accelerate adequate pharmacological or behavioral treatments for the reduction of mortality and morbidity.”

Heart failure can also progress to congestive heart failure, which occurs when fluid builds up in the limbs, lungs, and/or other organs as an indirect result of the heart’s weakened pumping. Systemic congestion is a major determinant of organ dysfunction and death in chronic heart failure patients. Currently, there is no reliable test that can diagnose congestion in its pre-symptomatic stages, which is needed so that healthcare providers can start or adjust decongestive therapy for patients before the condition worsens.

In a second paper, a group of researchers led by Alexandre Mebazaa, MD, of Université Paris Diderot showed that a test for the protein soluble CD146 (sCD146) could potentially detect congestion early. One of the initial signs of congestion is a subclinical increase of venous pressures. To determine if sCD146 is released as a response to this, the researchers compressed the dominant arm of 44 stable chronic heart failure patients and measured sCD146 levels in both arms at the start time and after 90 minutes. In the compressed arm, sCD146 levels increased significantly by 60 µg/L compared with a small 16 µg/L increase in the control arm. These results indicate that, if validated in larger studies, sCD146 could serve as a marker of increased venous pressure that signals the onset of congestion.

Both studies, by Mueller-Hennessen M et al and by Arrigo M et al, were published January 6, 2017, in the Cardiovascular Disease special issue of the journal Clinical Chemistry.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.